Apogee Therapeutics, Inc.

APGE • Biotechnology

$135.07

— 0.00 (0.00%)

Precio actual

ResultadosÚltimo reporte: 30 jun 2026

PERFIL DE MAYOR RIESGOPrecauciónConfianza: 62%

Perfil cuantitativo — no constituye una recomendación de inversión.

Perfil cuantitativo — no constituye una recomendación de inversión.Metodología

Tesis del análisis: Conviene actuar con cautela. Los ratios recientes muestran debilidades que pueden limitar el retorno si los fundamentales no mejoran.

Capitalización

$10.19B

Crecimiento

—

Flujo de caja

0/5

Tendencia

Negative

Evidencia

Nivel de deuda manejable · 0.01Liquidez saludable · 26.57Rentabilidad débil

Datos financieros hasta: 30 jun 2026, 12:00 a.m. UTCÚltima actualización de earnings: 30 jun 2026, 12:00 a.m. UTCÚltima actualización del perfil: 12 ago 2026, 12:07 p.m. UTC

Resumen de la compañía

Valoración, calidad, fortaleza financiera, momentum y datos de analistas.

Price$135.07

Change0.00%

Shares Out75.44M

Market Cap$10.19B

Enterprise Value$9.22B

52W Range34.58 - 134.88

Beta0.33

P/E-34.62

P/B8.53

P/FCF-41.77

EV/EBITDA-29.85

EV/FCF-37.79

Price$135.07

Change0.00%

Shares Out75.44M

Market Cap$10.19B

Enterprise Value$9.22B

52W Range34.58 - 134.88

Beta0.33

P/E-34.62

P/B8.53

P/FCF-41.77

EV/EBITDA-29.85

EV/FCF-37.79

Earnings Yield-2.89%

FCF Yield-2.39%

Dividend Yield0.00%

Gross Margin0.00%

Oper. Margin0.00%

Profit Margin0.00%

Debt/Eq0.01

Current Ratio26.57

Quick Ratio26.57

Target$130.92

Target Upside-3.07%

Target Median$135.00

Target Range89.00 - 140.00

Volume1.05M

Avg Volume2.06M

EPS Surprise0.01

ADN de inversión

Qué tan fuerte luce esta compañía para inversionistas de largo plazo

de 100

Calidad del negocio

Márgenes, ventaja competitiva, retornos

22/100

Fortaleza financiera

Deuda, caja, estabilidad

76/100

Potencial de crecimiento

Ingresos y expansión

50/100

Atractivo del precio

Barata o cara hoy

61/100

Por qué este puntaje▼

Nivel de deuda manejable · 0.01Liquidez saludable · 26.57Rentabilidad débil

Analyst view

Analyst sentiment and price target

APGE

Analyst sentiment

Based on 14 analyst votes · 2026-09-05

57/100

Neutral

Bullish

Hold

Bearish

Precio objetivo

2026-08-12

Bajo

$81.00

Promedio

$125.52

Mediana

$135.00

Alto

$140.00

Resumen de la compañía

IPO: 7/14/2023

Industria: Biotechnology

P/B i: 8.53

Deuda / Patrimonio i: 0.01

Margen operativo: 0.00%

Margen neto: 0.00%

ROE i: -

ROIC: -

Salud financiera

Puntaje15 / 20

Deuda / Patrimonio: 0.01

Ratio corriente: 26.57

Ratio rápido: 26.57

Estado: Good

Transacciones internas

Actividad reciente de ejecutivos e insiders

Fairmount Funds Management LLC

Transacción: 08/07/2026

VENTA

Cambio

-10,370

Precio

$43.85

Presentación

08/11/2026

Tipo

VENTA

Fairmount Funds Management LLC

Transacción: 08/07/2026

COMPRA

Cambio

+31,838

Precio

$17.00

Presentación

08/11/2026

Tipo

COMPRA

Dambkowski Carl

Transacción: 08/05/2026

VENTA

Cambio

-4,125

Precio

$22.86

Presentación

08/07/2026

Tipo

VENTA

Insider	Tipo	Cambio	Precio	Transacción	Presentación
Fairmount Funds Management LLC	VENTA	-10,370	$43.85	08/07/2026	08/11/2026
Fairmount Funds Management LLC	COMPRA	+31,838	$17.00	08/07/2026	08/11/2026
Dambkowski Carl	VENTA	-4,125	$22.86	08/05/2026	08/07/2026
Dambkowski Carl	VENTA	-5,500	$134.17	08/05/2026	08/07/2026
Henderson Jane	VENTA	-15,000	Not reported	07/24/2026	07/24/2026
Dambkowski Carl	VENTA	-8,000	Not reported	07/14/2026	07/16/2026
HENDERSON MICHAEL THOMAS	VENTA	-75,046	Not reported	07/10/2026	07/10/2026
HENDERSON MICHAEL THOMAS	VENTA	-20,000	$133.63	07/08/2026	07/10/2026
Dambkowski Carl	VENTA	-4,125	$22.86	07/01/2026	07/02/2026
Dambkowski Carl	VENTA	-5,500	$132.74	07/01/2026	07/02/2026
HENDERSON MICHAEL THOMAS	VENTA	-80,000	$132.54	06/22/2026	06/24/2026
Dambkowski Carl	VENTA	-26,400	$132.60	06/22/2026	06/24/2026
HENDERSON MICHAEL THOMAS	VENTA	-614	$86.89	06/10/2026	06/12/2026
Bollinger Lisa	COMPRA	+7,657	$85.00	06/09/2026	06/11/2026
Fox Jennifer A.	COMPRA	+7,657	$85.00	06/09/2026	06/11/2026
JONES WILLIAM A JR	COMPRA	+7,657	$85.00	06/09/2026	06/11/2026
McKenna Mark C.	COMPRA	+7,657	$85.00	06/09/2026	06/11/2026
Shah Nimish P	COMPRA	+7,657	$85.00	06/09/2026	06/11/2026
Fairmount Funds Management LLC	COMPRA	+7,657	$85.00	06/09/2026	06/11/2026
Dambkowski Carl	VENTA	-4,125	$22.86	06/03/2026	06/05/2026

Sobre la compañía

Apogee Therapeutics, Inc.

Apogee Therapeutics, Inc. is a biotechnology firm, operating via its subsidiary, dedicated to advancing biologic treatments for conditions such as atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and a range of other inflammatory and immunological disorders. Its primary focus includes APG777, a subcutaneous (SQ) monoclonal antibody (mAb) engineered for an extended half-life to treat AD, and APG808, a similarly formulated SQ extended half-life mAb targeting COPD. Furthermore, its earlier-stage pipeline features APG990, another SQ extended half-life mAb designed for AD, and APG222, comprising extended half-life subcutaneous antibodies also aimed at AD. Established in 2022, the company maintains its headquarters in Waltham, Massachusetts.

Fuente - Link

Competidores

AAPG CELC CGON CNTA IRON LEGN RARE SLNO XENE ZLAB

Tamaño = capitalización · color = línea del gráfico

Rendimiento de peers · 1A

Top performers + empresa seleccionada

Ultimas Noticias

AbbVie Completes Acquisition of Apogee Therapeutics

Acquisition deepens AbbVie's robust immunology pipeline with diverse assets targeting dermatologic, respiratory and other inflammatory and immunological diseases Apogee's lead asset, zumilokibart, is a late-stage, half-life extended monoclonal antibody targeting IL-13, in development for patients with atopic dermatitis Apogee's pipeline also includes APG273, a potential best-in-category long-acting combination targeting IL-13 and thymic stromal lymphopoietin (TSLP), in development for asthma AbbVie reaffirms previously issued 2026 full-year adjusted diluted EPS guidance range of $13.87 - $14.07; reaffirms previously issued third-quarter adjusted diluted EPS guidance range of $3.84 - $3.88 NORTH CHICAGO, Ill., Sept. 3, 2026 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that it has completed its acquisition of Apogee Therapeutics, Inc. (NASDAQ: APGE).

PRNewsWire

Deutsche Bank AG Acquires New Stake in Apogee Therapeutics Inc. $APGE

Deutsche Bank AG acquired a new stake in Apogee Therapeutics Inc. (NASDAQ: APGE) during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 98,979 shares of the company's stock, valued at approximately $13,137,000. Deutsche Bank AG owned approximately 0.16% of

Defense World

This Apogee Therapeutics Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.

Benzinga

Apogee Reports Second Quarter 2026 Financial Results and Recent Corporate and Pipeline Updates

AbbVie to acquire Apogee for $135.11 per share in cash for total equity value of approximately $10.9 billion, positioning differentiated immunology portfolio to reach more patients worldwide Positive 16-week Phase 2 APEX Part B induction dose optimization results support planned advancement of zumilokibart into Phase 3 development in moderate-to-severe atopic dermatitis this year SAN FRANCISCO and BOSTON, Aug. 10, 2026 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), a clinical-stage biotechnology company advancing optimized, novel biologics with the potential for best-in-class profiles in the largest inflammatory and immunology (I&I) markets, today reported second quarter 2026 financial results, recent corporate updates and pipeline progress. "The second quarter marked a transformational period for Apogee," said Michael Henderson, M.D.

GlobeNewsWire

Insider Selling: Apogee Therapeutics (NASDAQ:APGE) Insider Sells $737,935.00 in Stock

Apogee Therapeutics Inc. (NASDAQ: APGE - Get Free Report) insider Carl Dambkowski sold 5,500 shares of Apogee Therapeutics stock in a transaction on Wednesday, August 5th. The shares were sold at an average price of $134.17, for a total value of $737,935.00. Following the transaction, the insider directly owned 168,498 shares of the company's stock, valued

Defense World

Sorpresas de ganancias

Período	Estimado	Real	Sorpresa
2026-05-11	-1.07	-1.06	0.01
2026-03-02	-1.05	-1.03	0.02
2025-11-10	-1.12	-1.11	0.01
2025-08-11	-1.03	-1.13	-0.1
2025-05-12	-1.19	-0.95	0.24
2025-03-03	-0.94	-1.19	-0.25
2024-11-12	-0.87901	-0.86	0.01901
2024-08-12	-0.64	-0.6	0.04
2024-05-13	-0.6	-0.64	-0.04
2024-03-05	-0.45	-0.32	0.13
2023-11-13	-0.38	-0.51	-0.13
2023-07-17	-1.7	-3.78	-2.08